Apogee develops longer-acting eczema and asthma biologics.
Apogee Therapeutics, Inc. (APGE) is expected to report earnings on Monday, November 9, 2026, before the open. Estimated release time 07:07 ET. Consensus EPS estimate is $-1.14.
| Report date | Quarter | EPS est. | EPS actual | Surprise | Revenue |
|---|---|---|---|---|---|
| 2026-05-11 | Mar 2026 qtr | $-1.07 | $-1.06 | +0.9% | $0 |
| 2026-03-02 | Dec 2025 qtr | $-1.05 | $-1.03 | +1.9% | $0 |
| 2025-11-10 | Sep 2025 qtr | $-1.12 | $-1.11 | +0.9% | $0 |
| 2025-08-11 | Jun 2025 qtr | $-1.03 | $-1.13 | -9.7% | $0 |
| 2025-05-12 | Mar 2025 qtr | $-1.19 | $-0.95 | — | $0 |
| 2025-03-03 | Dec 2024 qtr | $-0.94 | $-1.22 | — | $0 |
| 2024-11-12 | Sep 2024 qtr | $-0.88 | $-0.86 | +2.2% | $0 |
| 2024-08-12 | Jun 2024 qtr | $-0.64 | $-0.60 | +6.3% | $0 |
APGE has beaten consensus EPS in 5 of its last 6 scored quarters.
See APGE on the live calendar →